As of 2025-07-04, the Intrinsic Value of Gemini Therapeutics Inc (GMTX) is - USD. This GMTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.35 USD, the upside of Gemini Therapeutics Inc is -100.00%.
Based on its market price of 1.35 USD and our intrinsic valuation, Gemini Therapeutics Inc (GMTX) is overvalued by 100.00%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
Range | Selected | Upside | |
a | |||
Fair Value | - - - | - | -100.00% |
P/E | (14.22) - (20.23) | (14.54) | -1176.7% |
DDM - Stable | (10.24) - (29.89) | (20.06) | -1586.2% |
DDM - Multi | (6.66) - (15.26) | (9.29) | -788.3% |
Market Cap (mil) | 58.49 |
Beta | 1.10 |
Outstanding shares (mil) | 43.33 |
Enterprise Value (mil) | -319.11 |
Market risk premium | 5.00% |
Cost of Equity | 9.32% |
Cost of Debt | 5.00% |
WACC | 6.50% |